Free Trial

DBV Technologies (DBVT) Competitors

DBV Technologies logo
$10.00 +0.29 (+2.99%)
Closing price 03:59 PM Eastern
Extended Trading
$10.30 +0.30 (+3.00%)
As of 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DBVT vs. ELVN, GPCR, CDTX, ARDX, PRAX, PROK, COLL, AKBA, AMPH, and RCUS

Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Enliven Therapeutics (ELVN), Structure Therapeutics (GPCR), Cidara Therapeutics (CDTX), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), ProKidney (PROK), Collegium Pharmaceutical (COLL), Akebia Therapeutics (AKBA), Amphastar Pharmaceuticals (AMPH), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

DBV Technologies vs. Its Competitors

DBV Technologies (NASDAQ:DBVT) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Enliven Therapeutics has lower revenue, but higher earnings than DBV Technologies. Enliven Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$4.15M66.00-$113.92M-$4.92-2.03
Enliven TherapeuticsN/AN/A-$89.02M-$1.92-11.80

Enliven Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,249.99%. Enliven Therapeutics' return on equity of -31.84% beat DBV Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
DBV Technologies-3,249.99% -278.24% -140.54%
Enliven Therapeutics N/A -31.84%-30.09%

DBV Technologies presently has a consensus target price of $14.75, indicating a potential upside of 47.50%. Enliven Therapeutics has a consensus target price of $41.20, indicating a potential upside of 81.82%. Given Enliven Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enliven Therapeutics is more favorable than DBV Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Enliven Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

DBV Technologies has a beta of -0.59, suggesting that its share price is 159% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

In the previous week, Enliven Therapeutics had 5 more articles in the media than DBV Technologies. MarketBeat recorded 6 mentions for Enliven Therapeutics and 1 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 1.28 beat Enliven Therapeutics' score of 0.71 indicating that DBV Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DBV Technologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Enliven Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 1.4% of DBV Technologies shares are held by company insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Enliven Therapeutics beats DBV Technologies on 12 of the 15 factors compared between the two stocks.

Get DBV Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DBVT vs. The Competition

MetricDBV TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$265.95M$2.91B$5.52B$9.41B
Dividend YieldN/A2.45%3.80%4.04%
P/E Ratio-2.0319.8828.0419.84
Price / Sales66.00305.11429.5399.59
Price / CashN/A43.1635.8457.94
Price / Book7.047.678.125.65
Net Income-$113.92M-$55.28M$3.25B$258.00M
7 Day Performance-7.41%2.50%0.97%2.09%
1 Month Performance1.52%11.70%7.36%11.13%
1 Year Performance140.96%4.89%31.31%18.40%

DBV Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DBVT
DBV Technologies
4.0198 of 5 stars
$10.00
+3.0%
$14.75
+47.5%
+142.8%$265.95M$4.15M-2.0380Positive News
ELVN
Enliven Therapeutics
2.8636 of 5 stars
$23.00
+2.4%
$41.20
+79.1%
-1.8%$1.13BN/A-11.9850News Coverage
GPCR
Structure Therapeutics
2.9436 of 5 stars
$19.57
+2.9%
$76.17
+289.2%
-49.1%$1.12BN/A-22.49136
CDTX
Cidara Therapeutics
3.6939 of 5 stars
$55.32
+9.5%
$57.29
+3.6%
+331.6%$1.12B$1.27M-1.8890Positive News
High Trading Volume
ARDX
Ardelyx
4.1637 of 5 stars
$4.61
+2.7%
$10.89
+136.2%
-21.4%$1.10B$333.61M-20.9590Analyst Revision
PRAX
Praxis Precision Medicines
2.4592 of 5 stars
$53.60
+6.1%
$94.11
+75.6%
-0.3%$1.09B$8.55M-5.00110News Coverage
Analyst Forecast
Analyst Revision
PROK
ProKidney
3.4049 of 5 stars
$3.69
-18.7%
$5.67
+53.6%
+53.0%$1.08B$306K-6.153Analyst Forecast
High Trading Volume
COLL
Collegium Pharmaceutical
4.4186 of 5 stars
$32.83
+1.0%
$43.75
+33.3%
+1.0%$1.05B$631.45M26.91210Positive News
AKBA
Akebia Therapeutics
3.7148 of 5 stars
$3.97
+1.0%
$6.75
+70.0%
+175.2%$1.04B$160.18M-18.90430
AMPH
Amphastar Pharmaceuticals
4.3171 of 5 stars
$21.95
+1.3%
$32.33
+47.3%
-45.0%$1.03B$731.97M7.952,028
RCUS
Arcus Biosciences
2.3406 of 5 stars
$9.66
+3.5%
$21.29
+120.5%
-39.0%$1.02B$258M-2.30500

Related Companies and Tools


This page (NASDAQ:DBVT) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners